← Back to Search

PD-1 Inhibitor

PT199 + Anti-PD-1 for Cancer

Phase 1
Recruiting
Research Sponsored by Phanes Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Able to provide a formalin fixed, paraffin embedded (FFPE) tumor tissue sample (archival tissue or fresh biopsy). To be assessed for CD73 and other biomarkers (PD-L1) expression
ECOG performance status of 0 or 1
Must not have
Autoimmune disease requiring systemic treatment within the past twelve months
Patients who have received chemotherapy, ≤ 5 half-lives or 3 weeks, whichever is shorter (6 weeks for nitrosourea or mitomycin-C), targeted therapy, or immunotherapy within 4 weeks prior to starting study drug
Timeline
Screening 3 weeks
Treatment Varies
Follow Up start of the study drug till 90 days after last dose.
Awards & highlights

Summary

This trial tests a new drug, PT199, which helps the immune system fight advanced cancers that haven't responded to other treatments. PT199 blocks a protein that helps cancer cells hide, making it easier for the immune system to attack them, especially when combined with other immune-boosting drugs.

Who is the study for?
This trial is for adults with advanced solid tumors that have worsened after standard treatments or when such treatments aren't suitable. Participants must have a performance status indicating they are fully active or restricted in physically strenuous activity but can do light work, and be able to provide tissue samples. Pregnant women, those with certain medical conditions, or who've had recent treatments excluded by the trial's criteria cannot participate.
What is being tested?
PT199 (an Anti-CD73 mAb) alone and combined with a PD-1 inhibitor are being tested in patients with advanced cancers. The study will assess safety, tolerability, how the body processes these drugs, their effects on the body and initial effectiveness against cancer progression.
What are the potential side effects?
Potential side effects include reactions at the injection site, fatigue, immune-related issues like inflammation of organs due to an overactive immune response which may require steroids for management; specific side effect profiles will be monitored closely given this is a first-in-human study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can provide a tissue sample for cancer biomarker testing.
Select...
I am fully active or can carry out light work.
Select...
My biopsy was not just a needle aspiration.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been treated for an autoimmune disease in the last year.
Select...
I haven't had chemotherapy, targeted therapy, or immunotherapy in the last 4 weeks.
Select...
I am a woman who can have children and do not use birth control.
Select...
I do not have severe health issues like uncontrolled high triglycerides or infections that could make the trial unsafe for me.
Select...
I have had lung inflammation treated with steroids or have a lung condition.
Select...
I have severe nerve damage.
Select...
I haven't had major radiation in the last 4 weeks or small area radiation in the last 2 weeks.
Select...
I am not on warfarin or similar blood thinners, but other types are okay.
Select...
I am not pregnant or breastfeeding.
Select...
I am allergic to some cancer immunotherapy drugs or their ingredients.
Select...
I have not had T-cell, NK cell, or CD73 inhibitor therapy but may have had PD-1 or PD-L1 inhibitors.
Select...
I stopped immune therapy due to side effects.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~start of the study drug till 90 days after last dose.
This trial's timeline: 3 weeks for screening, Varies for treatment, and start of the study drug till 90 days after last dose. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Recommended Phase 2 Dose of PT199 as a single agent and/or in combination with a PD-1 inhibitor.
To determine the maximum tolerated dose (MTD), if reached.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Part C: Combination Therapy Dose ExpansionExperimental Treatment2 Interventions
Approximately 8 additional patients will be treated in a dose expansion cohort at the MTD/DRDE. A minimum of 14 evaluable patients should be treated at DRDE before it can be declared as Recommend Phase II dose (RP2D). These can include the evaluable patients who were treated at DRDE in the dose escalation cohort(s). The RP2D may be declared based on the totality of safety, pharmacokinetics, and efficacy data from the dose escalation and dose expansion cohort, and upon the consensus of the Investigator(s), medical monitor, and Sponsor.
Group II: Part B: Combination Therapy Dose EscalationExperimental Treatment2 Interventions
A standard 3+3 dose escalation design will be employed, and 3 patients will be enrolled initially at each dose level. The starting dose of PT199 to be evaluated in the dose escalation study is 10 mg/kg weekly (QW). The dose level of PD-1 inhibitor, Tislelizumab in all provisional dose levels will be 200 mg once every 3 weeks (Q3W).
Group III: Part A: Monotherapy Dose EscalationExperimental Treatment1 Intervention
A standard 3+3 dose escalation design will be employed, and 3 patients will be enrolled initially at each dose level. The starting dose of PT199 to be evaluated in the dose escalation study is 10 mg/kg weekly (QW). Additional provisional dose levels include: 20 mg/kg QW, and 30 mg/kg QW.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tislelizumab
2018
Completed Phase 3
~4730

Find a Location

Who is running the clinical trial?

Phanes TherapeuticsLead Sponsor
2 Previous Clinical Trials
175 Total Patients Enrolled

Media Library

Anti-PD-1 monoclonal antibody (PD-1 Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05431270 — Phase 1
Pancreatic Cancer Research Study Groups: Part B: Combination Therapy Dose Escalation, Part A: Monotherapy Dose Escalation, Part C: Combination Therapy Dose Expansion
Pancreatic Cancer Clinical Trial 2023: Anti-PD-1 monoclonal antibody Highlights & Side Effects. Trial Name: NCT05431270 — Phase 1
Anti-PD-1 monoclonal antibody (PD-1 Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05431270 — Phase 1
~1 spots leftby Dec 2024